SCHEMBL1304367

SCHEMBL1304367

CC(C(=O)Nc1cccc2c1C(=O)c1c(NC(=O)C(C)N(C)C)cccc1C2=O)N(C)C

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TERT O14746 9/20 0.58
MAOA P21397 1/20 0.57
MAPT P10636 2/20 0.48
MEN1 O00255 1/20 0.48
ALDH1A1 P00352 1/20 0.48
POLB P06746 1/20 0.48
GAA P10253 1/20 0.48
DNMT1 P26358 1/20 0.48
RAD52 P43351 1/20 0.48
SMARCA2 P51531 1/20 0.48
KMT2A Q03164 1/20 0.48
EGFR P00533 1/20 0.47
PABPC1 P11940 1/20 0.47
MAPK1 P28482 1/20 0.47
RAB9A P51151 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
CDK4 P11802 1/20 0.45
CCND2 P30279 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1305345 0.86 TERT (0.56) TERTMAOAMAPTMEN1ALDH1A1
SCHEMBL1303757 0.82 TERT (0.55) TERTMAOAMAPTMEN1ALDH1A1
SCHEMBL10530825 0.82 MAOA (0.66) TERTMAOAMAPTMEN1ALDH1A1
SCHEMBL1304154 0.81 MAOA (0.59) TERTMAOAMAPTMEN1ALDH1A1
SCHEMBL9511573 0.80 MAOA (0.71) TERTMAOAMAPTMEN1ALDH1A1
SCHEMBL1303643 0.79 MAOA (0.57) TERTMAOAMAPTMEN1ALDH1A1
SCHEMBL5804633 0.78 MAOA (0.68) TERTMAOAMAPTMEN1ALDH1A1
SCHEMBL6366669 0.77 MAOA (0.62) TERTMAOAMAPTMEN1ALDH1A1
SCHEMBL29986841 0.76 MAOA (0.87) TERTMAOAMAPTALDH1A1GAA
SCHEMBL10136191 0.75 MAOA (0.64) TERTMAOAMAPTMEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8053583-B2 Anti-cancer compound and manufacturing method thereof NATIONAL DEFENSE MEDICAL CENTER (TW) 2011-11-08 US disclosed
US-20100145070-A1 ANTI-CANCER COMPOUND AND MANUFACTURING METHOD THEREOF NATIONAL DEFENSE MEDICAL CENTER (TW) 2010-06-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100145070-A1 ANTI-CANCER COMPOUND AND MANUFACTURING METHOD THEREOF DCK, DHPS, DHX15 TERT 3131/4885MAOA 1809/4885MAPT 4089/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.